Wednesday, June 10, 2026
🇺🇸 FDA

P0 · Therapeutic area intelligence

Neurology & CNS patent intelligence

Alzheimer's, Parkinson's, epilepsy, and CNS pharmaceutical patent landscape.

Patents
289

Quick answer

289 US pharmaceutical patents in our index match Neurology & CNS title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. WO 2026025082

    MÉTHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    BIOGEN MA INC [US] · Granted Thu Jan 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 24 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. AU 2025242171

    A Medicament and Method of Treatment of Central Nervous System and/or Neuropsychiatric Disorders

    BEIGENE SWITZERLAND GMBH [CH] · Granted Thu Dec 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Dec 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12427160

    Use of cannabinoids in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12419869

    Methods of treating multiple sclerosis

    VANDA PHARMACEUTICALS INC. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12410474

    Methods, kits, and devices for diagnosing, prognosing, and treating psychiatric disorders in a patient

    Northwestern University · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12409210

    CNS delivery of therapeutic agents

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2025184490

    N-[4-FLUOR-5-[[(2S,4R)-4-[(6-MÉTHOXY-4-PYRIMIDNYL)OXY]-2-MÉTHYL-1-PYRROLIDINYL]MÉTHYL]-2-THIAZOLYL]ACÉTAMIDE DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    BIOGEN MA INC [US] · Granted Thu Sep 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Aug 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12396988

    Methods of using muscarinic antagonists in the treatment of depression

    The Board of Regents of the University of Texas System · Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12390483

    Compounds and methods for treating neurological and cardiovascular conditions

    The Board of Regents of the University of Texas System · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12383567

    Use of cannabinoids in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12371414

    Methods of treating neurological disorders

    Neumora Therapeutics, Inc. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12370270

    Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders

    The Regents of the University of California · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12357616

    Methods of treating multiple sclerosis

    VANDA PHARMACEUTICALS INC. · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12358892

    Metalloenzyme inhibitors for treating cancers, Alzheimer's disease, hemochromatosis, and other disorders

    Miralogx LLC · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12357586

    Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12350253

    Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12329457

    Hyperspectral imaging for early detection of Alzheimer's disease

    Regents of the University of Minnesota · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12325691

    Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain

    The Board of Regents of the University of Texas System · Granted Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12318356

    Use of cannabinoids in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12319929

    Compositions and methods for the treatment of Parkinson's disease

    VOYAGER THERAPEUTICS, INC. · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12286407

    Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases

    The Regents of the University of California · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12280063

    Anti-retroviral therapies and reverse transcriptase inhibitors for treatment of Alzheimer's disease

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12274735

    IL-4-fusion formulations for treatment of central nervous system (CNS) tumors

    Medicenna Therapeutics Inc. · Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. WO 2025064824

    MÉTHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    BIOGEN MA INC [US] · Granted Thu Mar 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12239654

    Compounds and methods for treating neurological and cardiovascular conditions

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12241099

    Peptide therapeutics for treating Alzheimer's disease and related conditions

    The Board of Regents of the University of Oklahoma · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12168041

    Methods and compositions for CNS delivery of arylsulfatase A

    Takeda Pharmaceutical Company Limited · Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12161702

    Methods and compositions for CNS delivery of heparan N-sulfatase

    Takeda Pharmaceutical Company Limited · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12161755

    Sustained release device for treatment of Parkinson's disease and other disorders

    Regents of the University of Minnesota · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12156879

    Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy

    UNIVERSITY OF CONNECTICUT · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. WO 2024242579

    RÉGIMES DE TRAITEMENT DE LA MALADIE DE PARKINSON IDIOPATHIQUE PRÉCOCE

    BIAL PORTELA & CA SA [PT] · Granted Thu Nov 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Nov 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12150777

    Treatment of depression

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12144815

    Use of aprepitant for treating Alzheimer's disease

    Hoth Therapeutics, Inc. · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12146150

    Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery

    VOYAGER THERAPEUTICS, INC. · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12128014

    Use of thiol compounds to treat neurological disease

    MERCAPTOR DISCOVERIES, INC. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12121569

    Methods and compositions for CNS delivery of iduronate-2-sulfatase

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12090145

    Combination therapy for treating or preventing depression or other mood diseases

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12064399

    Use of cannabinoids in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12029759

    Compositions and methods for treating neurological disorders

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11998516

    Methods and compositions for treating depression using cyclobenzaprine

    TONIX PHARMA LIMITED · Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11993580

    Methods of treating neurological disorders

    Neumora Therapeutics, Inc. · Granted Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11975056

    AADC polynucleotides for the treatment of Parkinson's disease

    VOYAGER THERAPEUTICS, INC. · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11974992

    Use of serotonin 5-HT1A receptor agonists to treat diseases associated with sudden unexpected death in epilepsy

    The Regents of the University of California · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11951097

    Methods of treating multiple sclerosis

    VANDA PHARMACEUTICALS INC. · Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11911368

    Method of treatment of CNS disorders

    Supernus Pharmaceuticals, Inc. · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11911419

    Compositions and methods for treating epilepsy and related disorders

    Finch Therapeutics Holdings LLC · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. WO 2024039256

    RÉGIMES THÉRAPEUTIQUES POUR LA MALADIE DE PARKINSON

    BIAL PORTELA & CA SA [PT] · Granted Thu Feb 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11897875

    Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type a receptors as fast acting treatment for depression and mood disorders

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Neurology & CNS patents are indexed?

289 patents match our Neurology & CNS classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.